BRIEF‪—New appointments at Evox Therapeutics

Exosome specialist Evox Therapeutics has appointed Bo Kara as VP of process development and Simon Dew as VP of business development.

Dr Kara was previously head of process development at GlaxoSmithKline’s cell & gene therapy division, with responsibility for all aspects of process development. He has also worked as director of science and technology at Fujifilm Diosynth Biotechnologies.

Mr Dew was previously VP of corporate strategy at Gyroscope Therapeutics and has had corporate development roles at Astellas Pharmaceuticals, Bristol Myers Squibb and other pharma firms.